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Nonalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease worldwide and includes a broad
spectrum of histologic phenotypes, ranging from simple hepatic steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic
steatohepatitis (NASH). While liver biopsy is the reference gold standard for NAFLD diagnosis and staging, it has limitations
due to its sampling variability, invasive nature, and high cost. Thus, there is a need for noninvasive biomarkers that are robust,
reliable, and cost effective. In this study, we measured 540 lipids and amino acids in serum samples from biopsy-proven sub-
jects with normal liver (NL), NAFL, and NASH. Using logistic regression analysis, we identiﬁed two panels of triglycerides
that could ﬁrst discriminate between NAFLD and NL and second between NASH and NAFL. These noninvasive tests were
compared to blinded histology as a reference standard. We performed these tests in an original cohort of 467 patients with
NAFLD (90 NL, 246 NAFL, and 131 NASH) that was subsequently validated in a separate cohort of 192 patients (7 NL,
109 NAFL, 76 NASH). The diagnostic performances of the validated tests showed an area under the receiver operating char-
acteristic curve, sensitivity, and speciﬁcity of 0.88 6 0.05, 0.94, and 0.57, respectively, for the discrimination between
NAFLD and NL and 0.796 0.04, 0.70, and 0.81, respectively, for the discrimination between NASH and NAFL. When the
analysis was performed excluding patients with glucose levels >136 mg/dL, the area under the receiver operating characteristic
curve for the discrimination between NASH and NAFL increased to 0.81 6 0.04 with sensitivity and speciﬁcity of 0.73 and
0.80, respectively. Conclusion: The assessed noninvasive lipidomic serum tests distinguish between NAFLD and NL and
between NASH and NAFL with high accuracy. (Hepatology Communications 2018;2:807-820)
Introduction
Nonalcoholic fatty liver disease (NAFLD) rep-resents a spectrum of liver diseases that rangesfrom simple triglyceride (TG) accumulation
(nonalcoholic fatty liver [NAFL]) to fat accumulation
with inﬂammation and cellular injury (nonalcoholic
steatohepatitis [NASH]) that ultimately may progress
to ﬁbrosis, cirrhosis, and hepatocellular carcinoma.(1,2)
During the last 3 decades, the incidence of NAFLD
has substantially increased. It is now the most common
chronic disease of the liver, with a prevalence between
10% and 40% in Western countries. Approximately
10%-30% of patients with NAFLD progress to
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NASH.(3,4) Distinguishing between NASH and NAFL
and ascertaining the stage of ﬁbrosis are critical for dis-
tinguishing between a generally benign condition and
one with increased morbidity and mortality.(5) Cur-
rently, liver biopsy remains the gold standard for
NAFLD diagnosis and staging. However, it is an inva-
sive procedure and is limited by sampling error, high
cost, procedure-related complications, and observer vari-
ability, even when performed by expert pathologists.(6,7)
Therefore, there is an unmet need for noninvasive bio-
markers that are robust, reliable, and cost effective that
will allow practitioners not only to diagnose and stage
NAFLD but also to monitor NAFLD progression.
Such biomarkers could also be a useful addition to the
current design of NASH clinical trials.
Magnetic resonance imaging proton density fat frac-
tion (MRI-PDFF) and magnetic resonance elastogra-
phy (MRE) have emerged as accurate tools for
quantifying steatosis(8-10) and ﬁbrosis(11-13); however,
they have limitations in detecting inﬂammation, bal-
looning, and cellular injury. The latter are key compo-
nents in NASH diagnosis and part of the histologic
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criteria to monitor NASH progression in ongoing clin-
ical trials.(14) Therefore, there is an active search for
noninvasive NAFLD biomarkers measured mainly in
blood. These biomarkers include metabolites (lipids,
carbohydrates), peptides, proteins, and nucleic acids
(DNA, messenger RNA, microRNA).(15-18) Although
numerous possible biomarkers have been proposed,
few if any have been shown to have good accuracy and/
or have been validated against a large cohort of patients
with biopsy-proven NAFLD.
Metabolomics provides a powerful technology for
discovery of noninvasive biomarkers to improve diag-
nosis of complex diseases. Here, we applied liquid
chromatography–mass spectrometry (LC-MS) metab-
olomics to identify serum biomarkers that differentiate
between normal liver (NL) and NAFLD and bet-
ween NASH and NAFL in a cohort of 467 patients
with biopsy-proven NAFLD. These biomarkers were
subsequently validated using serum samples from a
separate cohort of 192 patients with biopsy-proven
NAFLD.
Patients and Methods
PATIENT COHORTS
A total of 467 biopsied adult patients (90 with NL,
246 with diagnosis of NAFL, and 131 with diagnosis
of NASH) seen at 11 participating hospitals formed
the discovery cohort. The full description of this cohort
has been described by Barr et al.(19) Patient characteris-
tics are summarized in Table 1. For the validation
group, an independent cohort of 239 biopsied adult
patients were recruited in ﬁve hospitals (Marques de
Valdecilla University Hospital, Santander, Spain;
Donostia University Hospital, Donosti, Spain; Virgen
de Valme University Hospital, Seville, Spain; Univer-
sity Clinic Hospital, Valladolid, Spain; and Faculty
General Hospital and the First Faculty of Medicine,
Charles University, Prague, Czech Republic). Principal
component analysis (PCA) of the serum metabolo-
mics data demonstrated that patients from both the
discovery and validation cohorts clustered together
(Fig. 1A). Likewise, PCA of the serum metabolomics
data showed that patients of the validation cohort clus-
tered together independently of the hospital of origin
(Fig. 1B) and sex (Fig. 1C), as shown in the discovery
cohort.(20) The inclusion criteria for both the discovery
and validation cohorts were (1) age 18-70 years; (2) no
known acute or chronic disease except for obesity or
type 2 diabetes based on medical history, physical
examination, and standard laboratory tests; and (3)
alcohol consumption was less than 20 g/day for women
and 30 g/day for men. Exclusion criteria included
other causes of liver disease, such as viral hepatitis.
For all subjects, diagnoses were established histolog-
ically through liver biopsy specimens. Histologic slides
were processed as usual, employing hematoxylin and
eosin and Masson’s trichrome stains. For the discovery
group, the histologic diagnosis of NAFLD was estab-
lished by a single liver pathologist in each participating
hospital, according to the criteria deﬁned by Kleiner
et al.(21) and Brunt et al.(22) Following assessment,
patients were classiﬁed by the pathologists into the fol-
lowing three histologic groups: (1) NL, (2) NAFL
(hepatic steatosis alone), and (3) NASH (presence as
determined by the pathologist). None of the patients
had cirrhosis. For the validation study, initially 239
patients were recruited. One liver pathologist (M.O.I.)
independently evaluated 178 biopsies; when there
was disagreement with the original diagnosis given by
TABLE 1. CLINICOPATHOLOGIC CHARACTERISTICS OF THE DISCOVERY AND VALIDATION COHORTS
Discovery Cohort Validation Cohort
Histology NL NAFL NASH NL NAFL NASH
n 90 246 131 7 109 76
Age (years) 44.8 6 13.1 42.7 6 12.2 45.1 6 10.8 43.1 6 11.0 45.0 6 11.3 48.1 6 12.4
Sex (Female %) 88.1*,† 70.4‡ 74.6‡ 71.4 51.4 56.6
BMI (kg/m2) 39.4 6 13.3† 42.9 6 11.4‡ 45.9 6 11.2 39.8 6 13.2 40.2 6 9.6 43.2 6 8.6
AST (U/L) 21.2 6 12.6*,† 35.2 6 29.0 31.2 6 33.0 25.6 6 14.2 31.4 6 18.6 38.1 6 35.3
ALT (U/L) 19.0 6 7.4 *,†,‡ 46.7 6 35.2 40.6 6 30.8‡ 38.4 6 37.7 49.4 6 40.0 52.1 6 47.5
Total fasting cholesterol (mg/dL) 186.2 6 32.5 203.4 6 42.6 204.9 6 43.1 170.4 6 27.1 198.0 6 41.6 206.2 6 41.7
Fasting triglycerides (mg/dL) 120.3 6 54.3 155.9 6 98.4 141.2 6 88.2 93.0 6 49.6 167.6 6 89.9 165.6 6 83.8
Fasting glucose (mg/dL) 102.1 6 34.7 109.5 6 29.7 111.0 6 38.1 91.4 6 15.5 111.8 6 32.5 119.7 6 42.5
All diagnoses were established histologically in liver biopsy specimens. Data are expressed as mean 6 SD. Signiﬁcant differences
between groups (P < 0.05) are represented by *NL–NAFLD, †NL–NASH, and ‡discovery-validation cohorts.
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the liver pathologist from each participating hospital,
a third experienced NAFLD pathologist (P.B.) inde-
pendently evaluated the biopsy and his diagnosis was
considered. Biopsies that showed total disagreement
among the three pathologists were excluded from the
analysis. The histopathologic deﬁnition of NASH was
determined by the joint presence of steatosis, lobular
inﬂammation, and hepatocellular ballooning on liver
specimens, independently of the total NAFLD activity
score (NAS).(23) Biopsies with only steatosis, steatosis
with inﬂammation but without ballooning, or steatosis
with ballooning but without inﬂammation were classi-
ﬁed as NAFL. Biopsies with NAS 5 0 were classiﬁed
as NL. We excluded patients if they had a histopatho-
logic reading of NAS 5 0 and ﬁbrosis >0, NAS >0
but steatosis 5 0, and samples with ﬁbrosis 5 4. Fol-
lowing these criteria, 192 patients were selected
for further analysis (7 NL, 109 NAFL, 76 NASH).
Clinical, biochemical, and histologic characteristics
obtained from the validation cohort are summarized in
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FIG. 1. PCA of samples included in the
discovery and validation cohorts. (A) PCA
analysis showed that patients clustered
together in the discovery and validation
cohorts. (B,C) PCA analysis also demon-
strated that patients clustered together
independently of the (B) hospital of origin
and (C) sex in the validation cohort. Hos-
pital of origin: 1, Marques de Valdecilla
University Hospital, Santander, Spain; 2,
Biodonostia Research Institute-Donostia
University Hospital, Donostia, Spain; 3,
Clinic University Hospital, University of
Valladolid, Valladolid, Spain; 4, Faculty
General Hospital and the First Faculty of
Medicine, Charles University, Prague,
Czech Republic; 5, Virgen de Valme Uni-
versity Hospital, Seville, Spain.
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Table 1. The protocol was performed in accordance
with the Helsinki Declaration and was approved by
the institutional review board at each of the parti-
cipating hospitals. All patients gave written informed
consent.
BLOOD SAMPLE DETAILS
Blood specimens were collected under fasting condi-
tions, and serum was prepared by incubating patient
venous blood in serum separator tubes before centrifu-
gation (2,500g, 15 minutes). Supernatants were ali-
quoted into cryovials and stored at –808C until
metabolomics analysis. Blood collection was carried
out on the day of liver biopsy; height and weight were
recorded at this time.
CHEMICALS
LC/MS-grade solvents were purchased from Sigma
Aldrich (St. Louis, MO) and Fisher Scientiﬁc (Pitts-
burgh, PA). Reference metabolite standard com-
pounds were obtained from Sigma Aldrich, Avanti
Polar Lipids (Alabaster, AL), and Larodan Fine
Chemicals (Malm€o, Sweden).
LIPIDOMIC PROFILING
Lipidomic proﬁles of the serum samples were
obtained as described.(19) Serum extracts were mixed
with sodium chloride (50 mM) and chloroform/meth-
anol (2:1) in 1.5 mL microtubes on ice. The extraction
solvent was spiked with a TG compound, TG(13:0/
13:0/13:0), not detected in unspiked human serum
extracts. TGs are glycerides in which the glycerol is
esteriﬁed with three fatty acid groups. TG(13:0/13:0/
13:0), in particular, consists of one chain of trideca-
noic acid at the C-1 position, one chain of tridecanoic
acid at the C-2 position and one chain of tridecanoic
acid acid at the C-3 position of the glycerol group.
After brief vortex mixing, the samples were incubated
for 1 hour at –20 8C. Once centrifuged at 16,000g for
15 minutes, the organic phase was collected and the
solvent removed. The dried extracts were then recon-
stituted in acetonitrile/isopropanol (1:1), centrifuged
(16,000g for 5 minutes), and transferred to vials for
ultra-performance LC coupled to MS time of ﬂight
(UPLC-MS-TOF) analysis.
Chromatography was performed on a 2.1-mm inter-
nal diameter 3 100 mm ACQUITY 1.7 lm C18
BEH column (Waters Corp., Milford, MA) using an
ACQUITY UPLC system (Waters Corp.). The col-
umn was maintained at 608C and eluted with a 10-
minute linear gradient. The mobile phase, at a ﬂow
rate of 400 lL/minute, initially consisted of 60% sol-
vent A (water with acetonitrile [2:3] 1 10 mM ammo-
nium formate) and 40% solvent B (acetonitrile with
isopropanol [1:9] 1 10 mM ammonium formate),
increasing to 100% B over 10 minutes. After 5
minutes, the mobile phase was reset to the initial com-
position in readiness for the subsequent injection,
which followed a 45-second system recycle time. The
sample volume injected onto the column was 3 lL.
The eluent was introduced into the mass spectrometer
(SYNAPT G2 system or Xevo G2 QTof (Waters
Corp.) by electrospray ionization, with capillary and
cone voltages set in the positive ion mode to 3,200 and
30 V, respectively. The nebulization gas was set to
1,000 L/hour and 5008C. The cone gas was ﬁxed at 30
L/hour, and the source temperature was maintained at
1208C. Centroid data were acquired over the mass
range of 50-1,200 Da, using an accumulation time of
0.2 seconds per spectrum. All spectra were mass cor-
rected in real time by reference to leucine enkephalin,
infused at 10 lL/minute through an independent ref-
erence electrospray, sampled every 10 seconds. An
appropriate test mixture of standard compounds were
analyzed before and after the entire set of randomized
sample injections in order to examine the retention
time stability, mass accuracy, and sensitivity of the sys-
tem throughout the course of the run, which lasted a
maximum of 48 hours per batch of samples injected.
In addition, two different types of quality control
(QC) samples were used to assess the data quality. The
QC samples were reference serum samples that were
evenly distributed over the batches and extracted and
analyzed at the same time as the clinical samples. The
ﬁrst QC (PromoCell Inc., Germany) was used for
both internal standard intrabatch and interbatch cor-
rection and was considered the QC calibration sample,
whereas the second QC (Sigma Aldrich) was used to
evaluate the overall reproducibility (QC validation
sample). Data were processed using the TargetLynx
application manager for MassLynx 4.1 software
(Waters Corp.). A set of predeﬁned retention time
mass-to-charge ratio pairs, corresponding to metabo-
lites included in the analysis, were fed into the pro-
gram. Associated extracted ion chromatograms (mass
tolerance window, 0.05 Da) were then peak detected
and noise reduced in both the LC and MS domains
such that only true metabolite-related features were
processed by the software. Normalization factors were
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calculated for each metabolite as described by
Martınez-Arranz et al.(24)
STATISTICAL ANALYSIS
Logistic regression analysis(25) was applied to
achieve a predictive signature capable of ﬁrst discrimi-
nating between NAFLD and NL and second between
NASH and NAFL, introducing BMI as a continuous
variable. A forward stepwise method was used as a var-
iable selection criterion where the process started with
no variables in the model and variables were added one
at a time as long as these inclusions were worthy. Once
a variable was added, the model was evaluated to
ensure its discriminatory capability. The process was
repeated until no more variables improved the model.
Variables with missing values were not included in the
analysis as they would provide useless information in
this classiﬁcation method. Receiver operating charac-
teristic (ROC) curve analysis was used to assess the
discriminatory power. Overall diagnostic accuracy for a
given two-class comparison was done by the area under
the ROC curve (AUROC) with its associated standard
error. Sensitivity, speciﬁcity, and positive and negative
predictive values (PPV and NPV, respectively) were
estimated. All calculations were performed using R
v.3.2(26) with caret, caTools, and ROC R (ROCR)
packages to produce ROC curves and AUROC esti-
mates and the MASS package to generate the logistic
regression analysis model.
Results
IDENTIFICATION OF
BIOMARKERS AND TEST
DEVELOPMENT
We have previously demonstrated that serum lipido-
mic proﬁling could be used to differentiate between
individuals with NL and patients with NAFLD.(19)
Additionally, we also demonstrated that serum lipido-
mics could differentiate between patients with NASH
and NAFL and that this differentiation improved if
subjects were categorized by their BMI.(19) This BMI-
dependent serum lipidomic test measures the probabil-
ity of a certain sample to belong to one of these three
groups: NL, NAFL, and NASH. In that previous
work, a total of 467 biopsy-proven samples, classiﬁed
as NL, NAFL, or NASH, were analyzed using three
different metabolic UPLC-MS platforms that mea-
sured 540 different lipids and amino acids.(19) Taking
this work as a reference point, the next steps were con-
ducted to reduce the complexity of the test by means
of reducing the number of metabolites that needed to
be measured as well as the required analytical plat-
forms. Hepatic TG accumulation is closely related to
NAFLD,(27) and there is a close correlation between
the content of speciﬁc molecular species of TG in the
liver and their relative content in serum.(20) Accord-
ingly, we hypothesized that the transition from NL to
NAFLD and the progression from NAFL to NASH
may be described by changes in speciﬁc molecular spe-
cies of TG in the liver and that these changes would be
reﬂected in serum. As serum TGs were one of the
studied lipid families that showed larger differences
among the groups studied in our previous work,(19)
here we focused on a group of 69 serum TGs (Sup-
porting Table S1) that could be measured using a sin-
gle UPLC-MS platform.
Different mathematical models (including random
forest, support vector machine, and logistic linear
regression analysis) were applied to the data to distin-
guish between the different stages of the disease (NL,
NAFL, and NASH). An ideal biomarker of NAFLD
is one that would distinguish signiﬁcantly in a dose-
dependent manner among the three diagnostic catego-
ries of NL, NAFL, and NASH. Out of the 69 selected
TGs that optimally fulﬁlled this criterion, two panels
totaling 28 TGs could be identiﬁed: one, integrated by
11 TGs, that signiﬁcantly differentiated between NL
and NAFLD but could not discriminate NASH from
NAFL and a second set of 20 TGs that signiﬁcantly
distinguished between NASH and NAFL but could
not separate NL from NASH (Fig. 2). Logistic regres-
sion analysis was applied to this set of TGs to distin-
guish between NL and NAFLD and between NASH
and NAFL. The objective of logistic regression analy-
sis is to ﬁnd the best ﬁtting model to explain the con-
nection between the dichotomous variable and a set of
independent conditions. In our case, those indepen-
dent conditions were the lipidomic features of the
panel of selected TGs and the BMI, which was intro-
duced in the algorithms as a continuous variable.
DIAGNOSTIC PERFORMANCE
IN THE DISCOVERY COHORT
To evaluate the diagnostic performance of both
tests, we assessed the AUROC curves (Fig. 3). When
used to distinguish between NAFLD and NL, the
AUROC was 0.90 6 0.02 with sensitivity, speciﬁcity,
PPV, and NPV of 0.98, 0.78, 0.89, and 0.88,
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respectively (Fig. 3A,C). The AUROC value for the
discrimination between NASH and NAFL was 0.95
6 0.01, with sensitivity, speciﬁcity, PPV, and NPV of
0.83, 0.94, 0.89 and 0.90, respectively (Fig. 3B,D).
DIAGNOSTIC PERFORMANCE
IN THE VALIDATION COHORT
For validation of these TG biomarkers of NAFLD,
we used serum samples from a new cohort of 192 adult
patients who underwent liver biopsy at ﬁve
participating hospitals and who were assigned to three
histologic groups using the histologic criteria described
in Patients and Methods. Both the discovery and vali-
dation cohorts were similar with respect to total fasting
cholesterol, TG, and glucose (Table 1). After measur-
ing the content of the TG biomarkers of NAFLD in
the serum samples of the validation cohort, we
analyzed their diagnostic performance using the logis-
tic regression algorithms described above. The rela-
tionship between the NAS and the diagnostic of
NASH using the biopsy histologic data or the serum
                                                                                                                                      
FIG. 2. Triglyceride distribution in the discrimination among patients with NL, NAFL and NASH: ANOVA plot representation.
The ANOVA plot is a scatter plot of the negative log10-transformed P values from the ANOVA test. This ANOVA plot is a
variation of the volcano plot and represents the effect of the TGs studied in three categories (NL, NAFL, and NASH). The distance
of a TG from the center indicates its signiﬁcance in the test. The position in the circle indicates the effect of each TG in the three
diagnostic categories represented by the bar plots. TGs outside the inner red circle are P < 0.05. Abbreviation: ANOVA, analysis of
variance.
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TG biomarkers showed a similar proﬁle, although 15%
of cases with NAS 5 0-2 were categorized as NASH
and a higher proportion of the NAS 5 4 biopsies were
classiﬁed as NASH using the lipidomic test (Fig. 4).
The relationship of the NAS and the histologic diag-
nostic of NASH was nearly identical to that pub-
lished.(21,22) Cases with NAS 5 4 were divided by
pathologists between NAFL and NASH, as
reported.(21,22) Taking this into account, we deﬁned
NASH borderline cases as those with a maximum
score for one of the features of the NAS and a score of
at least 1 for one of the other two features. Thus, for
instance, biopsies with NAS 5 4, steatosis 5 3, and
inﬂammation 5 1 or ballooning 5 1 were considered
borderline. Similarly, cases with NAS 5 5, steatosis 5
2, and inﬂammation 5 3 and no ballooning were also
considered borderline. Following this criteria, a total of
38 patients were considered as NASH borderline. The
AUROC value for the diagnosis of NAFLD (discrimi-
nation between NAFLD and NL) was 0.88 6 0.05
with accuracy, sensitivity, speciﬁcity, PPV, and NPV
of 0.92, 0.94, 0.57, 0.98, and 0.25, respectively (Fig.
5A,C). Of the 185 patients with NAFLD analyzed,
only 12 were incorrectly classiﬁed as NL, the majority
of them (8 cases) were patients with NAFL with mini-
mal steatosis (score 1) and NAS 5 1-2. The AUROC
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FIG. 3. NAFLD serum metabolic proﬁle for the discrimination between NL and NAFLD and between NAFL and NASH in the
discovery cohort. Obesity-dependent metabolic proﬁle of the 28 TGs that participate in the subsequent mathematical models for the
discrimination among patients with NL, NAFL and NASH. (A,B) Heatmap representation of the serum metabolic proﬁle obtained
from 467 subjects with NL (90), NAFL (246), and NASH (131) included in the discovery cohort. Each data point corresponds to
the relative ion abundance of a given TG (vertical axis) in an individual patient’s serum with respect to that found in the rest of the
study population, 0 being the mean value. For each heatmap, log-transformed ion abundance ratios for (A) NAFLD versus NL and
(B) NASH versus NAFL are depicted, as represented by the scales, where blue represents a decrease in TG abundance in NAFLD
versus NL and NASH versus NAFL and red represents an increase in TG abundance. (C,D) AUROC curves calculated (C) NAFLD
versus NL and (D) NASH versus NAFL.
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value for the diagnosis of NASH (discrimination
between NASH and NAFL) was 0.79 6 0.04, with
accuracy, sensitivity, speciﬁcity, PPV, and NPV of
0.77, 0.70, 0.81, 0.81, and 0.69, respectively (Fig.
5B,D). NASH borderline biopsies were not included
in the analysis as those were divided between both
diagnostic categories. Finally, if borderline biopsies
were included, the AUROC for the discrimination
between NAFL and NASH decreased to 0.68 6 0.04
(not shown).
ERROR RATES IN THE
DETERMINATION OF NASH
Next, we evaluated the impact of the stage of each
of the histologic features of the NAS (steatosis, inﬂam-
mation, and ballooning) on the accuracy of the TG
biomarkers to diagnose NASH. In terms of steatosis,
the diagnostic error rate in patients with NAFL and
steatosis score 1 and 2 was around 15% and for steato-
sis score 3 it was 60%, the majority of them (38 of 40)
corresponding to borderline cases (Supporting Fig.
S1A). The diagnostic error rate in patients with
NASH inversely correlated with the steatosis score (5
of 10 patients [50%] with score 1, 10 of 33 patients
[30%] with score 2, and 8 of 30 patients [27%] with
score 3) (Supporting Fig. S1A). With respect to
inﬂammation, the diagnostic error rate in patients with
NAFL was around 30% for scores 0 and 1, while 1 of
2 patients with score 2 was misclassiﬁed as NASH.
The degree of inﬂammation in patients with NASH
inversely correlated with the diagnostic error rate (21
of 63 patients with score 1, 2 of 9 patients with score
2, and 0 of 1 patient with score 3 were incorrectly clas-
siﬁed as NAFL) (Supporting Fig. S1B). In terms of
ballooning, the diagnostic error rate in patients with
NAFL was around 35% in cases with ballooning scores
0 and 1; the degree of ballooning in patients with
NASH inversely correlated with the diagnostic error
rate (21 of 58 patients with score 1 and 2 of 15 patients
with score 2 were incorrectly classiﬁed as NAFL)
(Supporting Fig. S1C). To identify how the degree of
ﬁbrosis would affect the performance of the diagnosis
of NASH, we estimated the diagnostic error rate for
the different values of ﬁbrosis. The average diagnostic
error rate in patients with NAFL was 30% when the
score of ﬁbrosis was 0-1 and 3 and was 67% when the
score was 2 (2 of 3 patients were incorrectly classiﬁed)
(Supporting Fig. S1D). Around 46% of patients with
NASH were incorrectly classiﬁed as NAFL when the
score of ﬁbrosis was 0; this decreased to around 30%
for scores 1-3 (Supporting Fig. S1D). Finally, the
effect of BMI and glucose concentration was also eval-
uated due to the well-known relationship among these
two variables and NASH.(28,29) The relationship
between the BMI and the diagnostic error rate of
NASH was constant and around 30% in the range of
25-60 kg/m2 (Supporting Fig. S1E). The average
diagnostic error rate for glucose was around 30% for
glucose levels <136 mg/dL, increasing to 60%-70%
for larger values (Supporting Fig. S1F). Accordingly,
when the analysis was performed excluding patients
with glucose levels >136 mg/dL, the AUROC for the
discrimination between NASH and NAFL increased
to 0.81 6 0.04, with sensitivity, speciﬁcity, PPV, and
NPV of 0.73, 0.80, 0.78, and 0.75, respectively (Sup-
porting Fig. S2).
Discussion
Liver biopsy remains the diagnostic test of choice
for NASH, but it is an invasive procedure and is lim-
ited by sampling error, high cost, procedure-related
complications, and observer variability, even when per-
formed by expert pathologists.(6,7) In this study, from a
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FIG. 4. Relationship between the NAS and the diagnosis of
NASH using different approaches. For each NAS, the fraction of
cases diagnosed as NASH is represented. The total number of
observations for each score (N) and the number of patients diag-
nosed as NASH are shown at the top of the graph. Blue, histo-
logic diagnosis as described in Patients and Methods; red,
diagnosis of NASH using the TG biomarkers.
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large cohort of patients with NAFLD with different
disease activity, we performed a detailed metabolomics
analysis from serum samples that showed good accu-
racy for distinguishing between NL and NAFLD and
NASH from NAFL. This lipidomic test provides
promising easy-to-perform serum biomarkers to differ-
entiate disease severity and potentially to monitor dis-
ease progression or improvement.
Many advances have appeared in relation to the
noninvasive diagnosis of NAFLD over the last decade.
MRI-PDFF and MRE have been demonstrated to be
accurate tools for the detection of steatosis(8-10) and
ﬁbrosis.(11-13) MRE performance to distinguish
various ﬁbrosis stages has been shown to have an
AUROC between 0.82 and 0.89(31) but has been lim-
ited to distinguish NAFL from NASH (AUROC of
0.70).(30) In addition, MRI-PDFF and MRE are
expensive and require special software. Furthermore,
these tests showed limited promise for discriminating
NAFL from NASH.
Many serum biomarkers have been reported to dif-
ferentiate between NAFLD and NL or to distinguish
NASH from NAFL, but none of them have been
established to be effective in a large cohort of patients
with biopsy-proven NAFLD(15-19) or have been
validated using an independent blind cohort. Cytokine
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FIG. 5. NAFLD serum metabolic proﬁle for the discrimination between NL and NAFLD and between NAFL and NASH in the
validation cohort. Obesity-dependent metabolic proﬁle of the 28 TGs that participate in the discrimination among NL, NAFL and
NASH for the patients included in the validation cohort. (A,B) Heatmap representation of the serum metabolic proﬁle obtained from
192 patients with NL (7), NAFL (109), and NASH (76) included in the validation cohort. Each data point corresponds to the rela-
tive ion abundance of a given TG (vertical axis) in an individual patient’s serum with respect to that found in the rest of the study
population, 0 being the mean value. For each heatmap, log-transformed ion abundance ratios (A) NAFLD versus NL and (B) NASH
versus NAFL are depicted, as represented by the scales, where blue represents a decrease in TG abundance in NAFLD versus NL
and NASH versus NAFL and red represents an increase in TG abundance. (C,D) AUROC curves calculated (C) NAFLD versus
NL and (D) NASH versus NAFL.
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keratin 18 initially gained interest and was sug-
gested in practice guidelines as a tool to distinguish
NAFLD from NASH. However, recent studies have
commented on its lack of reproducibility and reliabil-
ity.(31,32) The NAFLD-ﬁbrosis score is calculated
based on age, BMI, hyperglycemia or diabetes, aspar-
tate aminotransferase (AST), alanine aminotransferase
(ALT), platelets, and albumin (www.naﬂdscore.com),
while the FIB-4 index(33) is based on age, AST, ALT,
and platelets. These biomarkers along with the
enhanced liver ﬁbrosis score(34) and others are increas-
ingly used but usually targeted to test advanced ﬁbrosis.
In a recent study of 600 patients from a European con-
sortium in which biomarkers of NAFLD were studied,
the authors tested only a few biomarkers, mainly to
diagnose advanced ﬁbrosis. These markers included
SteatoTest, ActiTest, FibroTest, and FIB-4. They
found that the AUROC of these biomarkers ranged
from 0.80 to 0.88.(35) Some of these biomarkers have
been suggested by the recent European Association for
the Study of the Liver guidelines to assess the severity
of ﬁbrosis and rule out advanced stages.(23) However,
there were no recommendations on any biomarkers to
diagnose NASH; liver biopsy remained the only rec-
ommendation for this in the recent guidelines. The
objective of this study was the identiﬁcation of a panel
of TGs that, combined with the BMI and a classiﬁca-
tion algorithm, would accurately differentiate between
NL and NAFLD and distinguish NAFL from
NASH, in a cohort of 467 patients with liver biopsies.
We used MS lipidomics and then validated these pan-
els of biomarkers and the classiﬁcation algorithm in an
independent blind cohort of patients with biopsy-
proven NAFLD. Our serum biomarkers test is the ﬁrst
of its kind to distinguish between NL and NAFLD
and NAFL from NASH with high accuracy in a large
blinded validation cohort.
UPLC-MS is routinely used in analytical chemistry
laboratories for toxicity studies and diagnosis of inher-
ited metabolic disorders. The implementation and
growth in clinical laboratories will depend on the
emergence of new diagnosis tests as the one discussed
here.(36) MS lipidomics is a high-throughput technol-
ogy that can measure simultaneously hundreds of dif-
ferent lipid classes and molecular species in a small
volume of serum.(37-40) We ﬁrst demonstrated this
concept by showing that a panel of 540 lipids could
differentiate NAFLD from NL and NASH from
NAFL.(19) We also observed that categorizing patients
by their BMI improved the power of the classiﬁcation
algorithm.(41) Here, we have drastically reduced the
number of metabolites that were necessary to diagnose
NASH from a metabolomic proﬁle of roughly 540 lip-
ids and amino acids(19) to a panel of 28 TGs. TGs
were chosen because NAFLD is characterized by an
abnormal regulation of liver TG homeostasis(42,43) and
the observation that changes in the molecular species
of liver TGs are mirrored in serum.(44)
The performance of the lipidomic test that distin-
guishes between NL and NAFLD showed an
AUROC of 0.90 6 0.02 in the discovery cohort, a
value that was maintained when applied to the valida-
tion cohort (AUROC of 0.88 6 0.05) with a good
sensitivity of 0.94, indicating a low number of false-
negative cases.(45) The performance of the lipidomic
test that distinguishes between NASH and NAFL
showed an AUROC of 0.95 6 0.01 in the discovery
cohort. After validation, the test maintained a suitable
capacity to distinguish NASH from NAFL (AUROC
of 0.796 0.04) with a good speciﬁcity of 0.81, indicat-
ing that it may perform well for NASH diagnosis
because of low false-positive errors.(45) This test
divided patients classiﬁed as NASH borderline
between the two diagnostic categories (NAFL and
NASH), which agrees with previous studies.(21,22)
Analysis of the impact of the stage of each of the histo-
logic features of the NAS system on the accuracy of
the diagnostic test revealed that, in general, the error
rate of NASH diagnosis ranged between 20% and 40%
for the different values of the features of the NAS sys-
tem and between 30% and 60% for the different score
values of ﬁbrosis. The effect of BMI on the error rate
of NASH diagnosis was constant and around 30% in
the range of 25-60 kg/m2. This result is in line with
the fact that the BMI was introduced in the algorithms
as a continuous variable, modulating the effect of this
variable in the diagnostic performance of the tests.
However, the effect of glucose level was not taken into
account in the algorithms, and we observed an increase
in the error rate for glucose levels >136 mg/dL that
corresponded with decompensated diabetes. When the
analysis was performed excluding patients with glucose
levels >136 mg/dL, the AUROC for the discrimina-
tion between NASH and NAFL increased to 0.81 6
0.04, with sensitivity, speciﬁcity, PPV, and NPV of
0.73, 0.80, 0.78, and 0.75, respectively.
The differences found in both cohorts regarding sex,
ALT, and AST are not considered of great importance
for the diagnosis of NASH as we did not ﬁnd any evi-
dence of their inﬂuence in the study of the discovery
cohort.(19) Regarding sex, although the proportion of
female individuals was lower in the validation cohort,
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we did not see differences in the diagnosis related to
sex as can be observed in Fig. 1C where all the samples
clustered together independently of sex. PCA analysis
of the serum metabolomics data of both cohorts also
indicates that they are comparable. With regards to
age, although several studies have been published
highlighting the relationship between the prevalence of
NASH and age,(46,47) the average age was similar in
the different stages of the disease for both cohorts.
Mechanistically, the reason by which this group of
28 speciﬁc serum TGs served to differentiate between
NL and NAFLD and between NASH and NAFL is
not clear at ﬁrst glance. This panel included saturated
(TG[46:0], TG[48:0], TG[53:0]) and unsaturated
(TG[44:1], TG[48:1], TG[49:1], TG[52:1], TG
[53:1], TG[50:2], TG[54:5], TG[58:2], for instance)
TGs of different fatty acid lengths, which were always
increased in NAFLD compared to NL but were lower
in NASH than in NAFL. This may reﬂect an
impaired synthesis and release of very low-density lipo-
protein in NASH(48) and agrees with the observation
that NASH does not require a particular amount of
TG.(49)
Our study has both strengths and limitations. A
limitation is the cross-sectional nature of the analysis
in both the original and validation cohorts. Further
studies are needed to assess changes in our tests longi-
tudinally. Our test does not assess the degree of ﬁbro-
sis; however, noninvasive tests for ﬁbrosis, such as
enhanced liver ﬁbrosis, FIB-4, and MRE, are already
established, while we are introducing a new test to dis-
tinguish NAFL from NASH, which is an unmet need.
The test does not take into account the potential role
of noncompensated diabetes, ethnicity, age, patatin-
like phospholipase domain-containing 3 (PNPLA3)
genotype or the possible differences in the lipidomic
proﬁle that could be found between different NAFLD
phenotypes, for instance, metabolically healthy obese
subjects and metabolically unhealthy obese patients.
Therefore, additional efforts should be made to enrich
our cohort with patients of different conditions, eth-
nicities, and phenotypes. On the other hand, the
strength of our study includes the large sample size
with a validation cohort, multicenter samples, detailed
and standardized metabolomics and histologic analysis,
conﬁrmation of pathology reading by multiple pathol-
ogists (all experts in NAFLD), diagnosis with a central
reader assessing discrepancy between readers, and
ﬁnally the reproducibility of this accurate test in the
original and validation cohorts. Addressing these and
other limitations of this model will be important next
steps toward perfect discrimination between NAFL
and NASH in serum. In conclusion, two lipidomic
tests have been validated that provide an easy-to-use
tool to differentiate disease severity and potentially to
monitor disease progression.
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